Acute pancreatitis caused by bortezomib in multiple myeloma: a case report and literature review

Published on Jan. 15, 2023Total Views: 676 times Total Downloads: 245 times Download Mobile

Author: Liang YANG ¹ Zhen ZENG ¹ Chuan-Cui LUO ¹ Ling JIANG ¹ Xiu-Jun LI ²  Xun-Rong ZHOU ¹

Affiliation: 1. Department of Pharmacy, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China 2. Department of Hematology, The Second Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang 550001, China

Keywords: Bortezomib Acute pancreatitis Multiple myeloma Adverse drug reaction

DOI: 10.19960/j.issn.1005-0698.202301014

Reference: Liang YANG, Zhen ZENG, Chuan-Cui LUO, Ling JIANG, Xiu-Jun LI, Xun-Rong ZHOU.Acute pancreatitis caused by bortezomib in multiple myeloma: a case report and literature review[J].Yaowu Liuxingbingxue Zazhi,2023, 32(1): 99-102.DOI: 10.19960/j.issn.1005-0698.202301014.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

A case of adverse drug reaction caused by bortezomib in the treatment of acute pancreatitis (AP) in patients with multiple myeloma (MM) was reported. Combined with related literature and similar cases in the FDA adverse event reporting system (FAERS), the characteristics and prevention points of this kind of ADR were summarized and analyzed. It is recommended that when MM patients, especially elderly patients (age≥60 years old) are given bortezomib treatment, the occurrence of AP should be highly alert to, when upper abdominal pain occurs, it should be combined with relevant laboratory tests. Identify and treat symptomatically as soon as possible to avoid greater harm to patients.

Full-text

Please download the PDF version to read the full text: download

References

1.中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订)[J]. 中华内科杂志, 2022, 61(5): 480-487. DOI: 10.3760/cma.j.cn112138-20220309-00165.

2.Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014, 15(12): e538-548. DOI: 10.1016/S1470-2045(14)70442-5.

3.Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib)[J]. Cancer Invest, 2004, 22(2): 304-311. DOI: 10.1081/cnv-120030218.

4.Kane RC, Bross PF, Farrell AT, et al. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapyp[J]. Oncologist, 2003, 8(6): 508-513. DOI: 10.1634/theoncologist.8-6-508.

5.中华医学会外科学分会胰腺外科学组. 中国急性胰腺炎诊治指南(2021)[J]. 中华消化外科杂志, 2021, 20(7): 730-739. DOI: 10.3760/cma.j.cn112139-20210416-00172.

6.Elouni B, Ben Salem C, Zamy M, et al. Bortezomib-induced acute pancreatitis[J]. JOP, 2010, 11(3): 275-276. https://pubmed.ncbi.nlm.nih.gov/20442528/.

7.Li Destri G, Innao V, Petrillo G, et al. A rare pancreatic pseudoaneurysm in patient with acute pancreatitis and multiple myeloma[J]. Ann Ital Chir, 2011, 82(4): 301-304. https://pubmed.ncbi.nlm.nih.gov/21834481/.

8.Solakoglu T, Akyol P, Guney T, et al. Acute pancreatitis caused by bortezomib[J]. Pancreatology，2013, 13(2): 189-190. DOI: 10.1016/j.pan.2013.01.002.

9.Mihăilă RG. A possible rare complication of bortezomib treatment: acute pancreatitis[J]. Acta Medica Transilvanica, 2013, 2(1): 269-271. https://www.researchgate.net/publication/281491412_A_POSSIBLE_RARE_COMPLICATION_OF_BORTEZOMIB_TREATMENT_ACUTE_PANCREATITIS.

10.Solakoglu T, Akar M, Aktan Kosker T, et al. Is bortezomib a rare cause of acute pancreatitis?[J]. JOP, 2013, 14(6): 682-683. DOI: 10.6092/1590-8577/1927.

11.Gupta H, Bansal R, Khanna S, et al. An unusual complication of bortezomib therapy: acute pancreatitis[J]. Indian J Nephrol, 2014, 24(2): 135-136. DOI: 10.4103/ 0971-4065.127928.

12.Talamo G, Sivik J, Pandey MK, et al. Bortezomib-induced acute pancreatitis: Case report and review of the literature[J]. J Oncol Pharm Pract, 2016, 22(2): 332-334. DOI: 10.1177/1078155214563813.

13.Wang HH, Tsui J, Wang XY, et al. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma[J]. Leuk Lymphoma, 2014, 55(6): 1404-1405. DOI: 10.3109/10428194.2013.831850.

14.Brulc E, Seehaus C, Schutz N, et al. Management of pancreatitis related to Bortezomib treatment: report of two cases[J]. Hematol Transfus Cell Ther, 2018, 40(4): 382-384. DOI: 10.1016/j.htct.2018.03.003.

15.Junquera Alonso E, Seoane Blanco L, Cano Calderero FX. Bortezomib-induced acute pancreatitis, an uncommon adverse event[J]. Rev Esp Enferm Dig, 2021, 113(1): 77. DOI: 10.17235/reed.2020.7120/2020.

16.Meltzer LE, Palmon FP Jr, Paik YK, et al. Acute pancreatitis secondary to hypercalcemia of multiple myeloma[J]. Ann Intern Med, 1962, 57: 1008-1012. DOI: 10.7326/0003-4819-57-6-1008.

17.Lee KH, Lee JS, Kim SH. Acute pancreatitis in a case of multiple myeloma with hypercalcemia[J]. Korean J Intern Med, 1989, 4(2): 178-180. DOI: 10.3904/kjim.1989.4.2.178.

18.Ito T, Kimura T, Yamashita S, et al. Acute pancreatitis associated with hypercalcemia in a patient with multiple myeloma[J]. Pancreas, 1992, 7(3): 396-398. DOI: 10.1097/00006676-199205000-00020.

19.Celik I, Apraş S, Kars A, et al. Persistent hypercalcemia leading to acute pancreatitis in a patient with relapsed myeloma and renal failure[J]. Nephron, 1998, 79(1): 109-110. DOI: 10.1159/000045004.

20.Mishra SB, Azim A, Mukherjee A. Multiple myeloma presenting as acute pancreatitis[J]. Am J Emerg Med, 2017, 35(9): 1385.e1-1385.e2. DOI: 10.1016/j.ajem.2017. 06.009.

21.Jo IH, Paik CN. Acute pancreatitis with hypercalcemia as initial manifestation of multiple myeloma[J]. Korean J Gastroenterol, 2020, 75(4): 220-224. DOI: 10.4166/kjg.2020.75.4.220.

22.Okamura D, Starr ME, Lee EY, et al. Age-dependent vulnerability to experimental acute pancreatitis is associated with increased systemic inflammation and thrombosis[J]. Aging Cell, 2012, 11(5): 760-769. DOI: 10.1111/j.1474-9726.2012.00841.x.

23.Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study[J]. Lancet Oncol, 2011, 12(5): 431-440. DOI: 10.1016/S1470-2045(11)70081-X.

24.Mateos MV. Subcutaneous bortezomib: a step towards optimised drug use[J]. Lancet Oncol, 2011, 12(5): 410-411. DOI: 10.1016/S1470-2045(11)70098-5.

25.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.